These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14986269)

  • 41. Community-acquired pneumonia in children: from diagnosis to treatment.
    Greenberg D; Leibovitz E
    Chang Gung Med J; 2005 Nov; 28(11):746-52. PubMed ID: 16422179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J; House HR; Siegel RE
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of ertapenem against bacteraemic pneumococci: report of a French multicentre study including 339 strains.
    Decousser JW; Methlouthi I; Pina P; Allouch P;
    J Antimicrob Chemother; 2005 Mar; 55(3):396-8. PubMed ID: 15705639
    [No Abstract]   [Full Text] [Related]  

  • 44. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
    Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
    Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel agents for the treatment of outpatient respiratory tract infections. Introduction.
    Pell DM
    Postgrad Med; 2002 Sep; 112(3 Suppl):5-6. PubMed ID: 19667592
    [No Abstract]   [Full Text] [Related]  

  • 47. Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.
    Groeneveld GH; van der Reyden TJ; Joosten SA; Bootsma HJ; Cobbaert CM; de Vries JJC; Kuijper EJ; van Dissel JT
    J Antimicrob Chemother; 2019 Aug; 74(8):2385-2393. PubMed ID: 31106377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association].
    Strålin K; Goscinski G; Hedlund J; Lidman C; Spindler C; Ortqvist A; Holmberg H
    Lakartidningen; 2008 Sep 17-23; 105(38):2582-7. PubMed ID: 18846863
    [No Abstract]   [Full Text] [Related]  

  • 49. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase.
    Elliott E; Brink AJ; van Greune J; Els Z; Woodford N; Turton J; Warner M; Livermore DM
    Clin Infect Dis; 2006 Jun; 42(11):e95-8. PubMed ID: 16652304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review.
    Falagas ME; Siempos II; Bliziotis IA; Panos GZ
    Mayo Clin Proc; 2006 Dec; 81(12):1567-74. PubMed ID: 17165635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
    Mills GD; Oehley MR; Arrol B
    BMJ; 2005 Feb; 330(7489):456. PubMed ID: 15684024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
    Torralba MÁ; Matía M; Gómez del Valle C; Pérez-Calvo JI
    Med Clin (Barc); 2010 Oct; 135(12):576-7. PubMed ID: 19819496
    [No Abstract]   [Full Text] [Related]  

  • 53. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the microbiologist].
    Quentin C
    Presse Med; 1998 Sep; 27 Suppl 4():12-3. PubMed ID: 9798477
    [No Abstract]   [Full Text] [Related]  

  • 54. [Initial treatment can lighten low-severity community-acquired pneumonia].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):413. PubMed ID: 16309029
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral β-Lactam Antibiotics for Pediatric Otitis Media, Rhinosinusitis, and Pneumonia.
    Molloy L; Barron S; Khan N; Abrass E; Ang J; Abdel-Haq N
    J Pediatr Health Care; 2020; 34(3):291-300. PubMed ID: 32334748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Doxycycline for treatment of community-acquired pneumonia.
    Johnson JR
    Clin Infect Dis; 2002 Sep; 35(5):632; author reply 632-3. PubMed ID: 12173142
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-course treatment of community-acquired pneumonia.
    Mandell LA; File TM
    Clin Infect Dis; 2003 Sep; 37(6):761-3. PubMed ID: 12955635
    [No Abstract]   [Full Text] [Related]  

  • 60. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children.
    Chiba N; Kobayashi R; Hasegawa K; Morozumi M; Nakayama E; Tajima T; Iwata S; Ubukata K;
    J Antimicrob Chemother; 2005 Oct; 56(4):756-60. PubMed ID: 16131518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.